Algorae Pharmaceuticals is now in discussions with Australian-based laboratories to start the precursor studies of the new drug combinations.

Algorae Pharmaceuticals executive chairman David Hainsworth said: This significant expansion highlights the important competitive advantage of AI to predict new therapeutic entities ahead of our competitors relying on conventional approaches. Targets that show promise in laboratory studies will either be developed internally or earmarked for potential development with a partner.”

AlgoraeOS is a cutting-edge AI system that uses complex algorithms and machine-learning models to predict new combinations of existing drugs that, when put together, could have an even greater impact on a disease than they would if applied individually.

The entire process is being run off Australia’s “GADI” super-computer, operated by National Computational Infrastructure, which has also been used for climate modelling and nature disaster prediction.

GADI can rapidly process huge scientific and medical datasets, which can then uncover new fixed-dose drug combinations that could improve therapeutic outcomes, reduce side effects and potentially lead to novel drug applications.

Building on the success of version 1, Algorae is actively developing version 2.0 of AlgoraeOS. It says the next model is likely to include bigger pharmaceutical databases, more powerful predictive AI modelling and an expanded range of disease targets. The second version will also not be limited to including cannabidiol as one of the drugs in each combination.

Earlier in the year, the company proved the value of using AI to reveal new drug combinations when it made a significant breakthrough in pre-clinical testing aimed at treating dementia.

By combining the long-term front-line drug treatment Donepezil with cannabidiol, the company showed the pairing significantly improved patient outcomes by increasing cell survival rates from 17 per cent to more than 50 per cent.

Algorae is quickly making a name for itself in the AI-driven drug development sector, tackling big healthcare challenges.

Whilst some are wary about the dangers associated with AI, particularly in the military sector, others hail it as a revolution. Algorae’s use of a super-computer and artificial intelligence to create ideas about drug combinations that could eventually cure some of the worst ailments of our time is ground-breaking and represents the very best that AI has to offer.

Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au